Are balding babies a growing epidemic? Toppik challenges the online world to this question in their new video, “Are Babies Going Bald?”
The answer, of course, is no, but by masquerading hair loss on the cutest of subjects, the one minute video campaign demonstrates the efficacy of the favorite cult solution, Toppik Hair Building Fibers, for filling in the finest of fine hair in an undetectable and instant way. Baby hair is notoriously thin with sporadic growth patterns, making it the perfect base for natural Toppik to showcase its proven, inconspicuous results in the series of before and after footage.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/63124-toppik-video-are-babies-going-bald
Treating Gum Disease At Home Does Not Have To Be Complicated. Especially when you are given step by step instructions on what to do.
This video gives you a complete gum disease healing programme that you need to follow strictly if you want to see results.
In 3-6 months time you should be gum disease free but only if you stick to this programme and don't deviate!
Below you will find links to some useful resources and products you will need to start this healing programme:
Blotting technique for teeth video: https://www.youtube.com/watch?v=pcu8q1PwI6o
Pure Acerola Powder for Vitamin C: https://amzn.to/2uphcbs
Cod Liver Oil For Vitamin A & D: https://amzn.to/38VmIlc
White Oak Powder: https://amzn.to/2HNMuvB
Sea Salt: https://amzn.to/2HONa41
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
WebMD and Scripps Translational Science Institute (STSI) today announced a new investigative study designed to improve researchers’ and health care professionals’ understanding of what contributes to healthy pregnancies and positive pregnancy outcomes. The Healthy Pregnancy Study will use WebMD’s newly redesigned and enhanced Pregnancy app for iPhone. Incorporation of the Apple ResearchKit software framework will enable survey participants to eConsent, easily and anonymously answer questions, and share connected device data about their pregnancies with researchers for analysis.
“Pregnant women are one of the least studied populations in medical research,” said Dr. Eric Topol, director of STSI and editor-in-chief of Medscape. “The results of our Healthy Pregnancy Study -- on the foundation of an exceptionally popular smartphone app -- will ultimately provide expectant mothers, researchers, and health care professionals with new medical insights to avoid complications during pregnancy.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7579757-webmd-stsi-healthy-pregnancy-study-app/
In order to succeed in today’s B2B sales world, salespeople must create buyer consensus among diverse customer stakeholders. Those who fail to do that risk falling victim to the status-quo – the minimal-risk, lowest-cost option – or worse, losing the deal altogether. The Challenger Customer: Selling to the Hidden Influencer Who Can Multiply Your Results from CEB (NYSE: CEB), a best practice insight and technology company, reveals that it isn’t just about how you engage, but who you engage within the customer organization that drives complex sales today.
“The ‘senior decision-maker’ no longer exists in B2B sales. That makes the most significant problem facing marketing and sales teams a buying problem, not a selling problem. Organizations need to shift their focus from making the sale to understanding buyer groups – and who among them really shapes decisions,” said co-author Brent Adamson, executive advisor at CEB. “Our research shows that the one thing that matters most to executives is whether or not a supplier has buy-in with the rest of the organization – NOT the supplier’s actual offering or solution.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7427252-ceb-the-challenger-customer/
If you are short in magnesium, you may not show any symptoms, you may just ignore them, or you may attribute them to some other nutrient deficiency. However, moderate or severe magnesium deficiency results in malnutrition, loss of appetite, nausea, weakness, personality changes, and arrhythmias.
Watch as Beaver Creek shows you the different ways to test your golf cart battery. You\'ll find out what battery testers are available to Beaver Creek Golf Carts and what battery testers you can use at home. We\'ll show you how to test your golf cart battery, how to read the results to know if your battery is still good or if it needs replacing.
The welcome address at this year’s Forum was delivered by Sergei Prikhodko, Deputy Prime Minister of the Russian Federation, Chief of Staff of the Government of the Russian Federation and Chairman of the Organizing Committee of the St. Petersburg International Economic Forum.
The Forum programme was unique in both scope and the subjects covered by a total of over 150 events.
This year, a new approach was taken to forming the interesting programme, involving the expert community.
According to the participants, “the discussions were more substantive, direct and open and the ideas expressed at the sessions will undoubtedly be of use in their work going forward”.
A group of our experts worked at all the events, the outcome of which will be a selection of proposals on the results of the business programme for presentation to the President of the Russian Federation.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7559951-st-petersburg-economic-forum/
Heute fand im „Maison de la Chimie“ in Paris die Pressekonferenz #ChangeTheNumbers der L’Oréal-Stiftung statt. Dort wurden die Ergebnisse einer exklusiven internationalen Studie vorgestellt, die gemeinsam mit dem Meinungsforschungsinstitut „Opinion Way“ durchgeführt wurde. Ziel der Untersuchung war es, die Gründe für das Ungleichgewicht in der Wissenschaft zwischen Frauen und Männern besser zu verstehen sowie Hindernisse aufzudecken, denen Frauen bei einer Karriere in der Wissenschaft gegenüberstehen.
David Macdonald, Direktor des Förderprogramms For Women in Science von L’Oréal betonte auf der Veranstaltung, dass sich die Öffentlichkeit nicht darüber bewusst sei, wie stark die Vorurteile über Frauen in der Wissenschaft noch immer in den Köpfen der Menschen verankert sind. Heute bewegt sich der Frauenanteil in der Wissenschaft nach wie vor auf geringem Niveau: Nur 30 % aller Forscher sind weiblich.1
Als Ergänzung zu dieser Studie hat die L’Oréal-Stiftung darüber hinaus Erfahrungsberichte von Preisträgerinnen, die im Rahmen des For Women in Science Programmes ausgezeichnet wurden, hinzugezogen. Besonders stolz ist die Stiftung auf die Unterstützung von Elizabeth Blackburn, L’Oréal-UNESCO For Women in Science Preisträgerin und Nobelpreisträgerin für Physiologie oder Medizin 2009. Elizabeth Blackburn
To view the multimedia release go to:
http://www.multivu.com/players/de/7624751-loreal-foundation-results-study/
Evidence from the Childhood Cancer Survivor Study suggests that changes in childhood cancer treatment have reduced deaths from the late effects of cancer treatment and extended the lives of childhood cancer survivors. St. Jude Children’s Research Hospital investigators led the research, which will be presented today at the plenary session of the 2015 annual meeting of the American Society of Clinical Oncology (ASCO).
The study is one of four being featured at the plenary session press briefing, which highlights research that ASCO deems as having the highest scientific merit and greatest potential to affect patient care.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7532851-st-jude-cancer-research/
The latest small overlap front crash test results from the Insurance Institute for Highway Safety (IIHS) reveal a range of performance among many of the best-selling small cars in the U.S. market. Of the 12 models evaluated, half earn a good or acceptable rating and qualify for the IIHS TOP SAFETY PICK+ award.
The 2-door and 4-door models of the Honda Civic are the only small cars to earn the top rating of good in the test. IIHS evaluated the Civics earlier this year and released the results in March. The Dodge Dart, Ford Focus, Hyundai Elantra and 2014 model Scion tC earn acceptable ratings.
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
